282 related articles for article (PubMed ID: 28110254)
1. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era.
Remon J; Le Rhun E; Besse B
Cancer Treat Rev; 2017 Feb; 53():128-137. PubMed ID: 28110254
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
3. Prolonged overall survival of patients with leptomeningeal carcinomatosis from nonsmall cell lung cancer.
Ju Y; Sun S; Wang J; Jiao S
J Cancer Res Ther; 2016 Oct; 12(Supplement):126-129. PubMed ID: 27721269
[TBL] [Abstract][Full Text] [Related]
4. The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer.
Gainor JF; Ou SH; Logan J; Borges LF; Shaw AT
J Thorac Oncol; 2013 Dec; 8(12):1570-3. PubMed ID: 24389440
[TBL] [Abstract][Full Text] [Related]
5. Intraventricular chemotherapy for leptomeningeal carcinomatosis from lung cancer: a feasible and beneficial treatment option?
Christoph DC; Reckamp KL
J Thorac Oncol; 2013 May; 8(5):523-4. PubMed ID: 23584292
[No Abstract] [Full Text] [Related]
6. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.
Liao BC; Lee JH; Lin CC; Chen YF; Chang CH; Ho CC; Shih JY; Yu CJ; Yang JC
J Thorac Oncol; 2015 Dec; 10(12):1754-61. PubMed ID: 26334749
[TBL] [Abstract][Full Text] [Related]
7. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.
Ahn HK; Han B; Lee SJ; Lim T; Sun JM; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2012 May; 76(2):253-4. PubMed ID: 22385925
[TBL] [Abstract][Full Text] [Related]
8. Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis.
Kamath SD; Kumthekar PU; Kruser TJ; Mohindra NA
Oncologist; 2018 Dec; 23(12):e159-e161. PubMed ID: 30072392
[TBL] [Abstract][Full Text] [Related]
9. Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR-mutant non-small cell lung cancer.
Mizusaki S; Otsubo K; Ninomiya T; Arimura H; Tsuchiya-Kawano Y; Inoue K
Thorac Cancer; 2021 Jan; 12(1):114-116. PubMed ID: 33112047
[TBL] [Abstract][Full Text] [Related]
10. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
Gong L; Xiong M; Huang Z; Miao L; Fan Y
Lung Cancer; 2015 Sep; 89(3):268-73. PubMed ID: 26141219
[TBL] [Abstract][Full Text] [Related]
11. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
[TBL] [Abstract][Full Text] [Related]
12. Management of leptomeningeal metastases in non-small cell lung cancer.
Patil S; Rathnum KK
Indian J Cancer; 2019 Nov; 56(Supplement):S1-S9. PubMed ID: 31793437
[TBL] [Abstract][Full Text] [Related]
13. Prolonged response of meningeal carcinomatosis from non-small cell lung cancer to salvage intrathecal etoposide subsequent to failure of first-line methotrexate: a case report and literature review.
Park MJ
Am J Case Rep; 2015 Apr; 16():224-7. PubMed ID: 25879815
[TBL] [Abstract][Full Text] [Related]
14. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.
Gwak HS; Joo J; Kim S; Yoo H; Shin SH; Han JY; Kim HT; Lee JS; Lee SH
J Thorac Oncol; 2013 May; 8(5):599-605. PubMed ID: 23422833
[TBL] [Abstract][Full Text] [Related]
15. Four-Year Lasting Sustained Complete Response After Nivolumab in a Patient With Non-Small-Cell Lung Cancer and Confirmed Leptomeningeal Carcinomatosis: Changing the Paradigm.
Bover M; Yarza R; Docampo LI
Clin Lung Cancer; 2020 Jan; 21(1):e1-e5. PubMed ID: 31601524
[No Abstract] [Full Text] [Related]
16. Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions.
Lee DW; Lee KH; Kim JW; Keam B
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399673
[TBL] [Abstract][Full Text] [Related]
17. [Intrathecal methotrexate chemotherapy for leptomeningeal carcinomatosis].
Kullmann T; Gauthier H; le Maignan C; Szabó A; Culine S
Orv Hetil; 2012 Sep; 153(35):1385-8. PubMed ID: 22935431
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of leptomeningeal carcinomatosis from gastric cancer].
Okuda T; Kataoka K; Kato A
Gan To Kagaku Ryoho; 2009 Apr; 36(4):599-603. PubMed ID: 19381031
[TBL] [Abstract][Full Text] [Related]
19. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
Kuiper JL; Smit EF
Lung Cancer; 2013 Apr; 80(1):102-5. PubMed ID: 23375403
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
Zhou T; Zhu S; Xiong Q; Gan J; Wei J; Cai J; Liu A
BMC Cancer; 2023 Apr; 23(1):333. PubMed ID: 37041504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
